The European Medicines Agency (EMA) has four mission-critical task forces which support its human and veterinary medicines divisions, bringing together expertise to drive transformational change in high-priority areas of the Agency's work.
The Digital Business Transformation task force drives complex, digital change initiatives that impact on EMA's strategy, operational structure and operations in relation to the European medicines regulatory network, its partners and stakeholders. This includes adapting EMA operations to fundamental changes brought by legislative initiatives, digital technologies and global trends to meet stakeholders’ needs and expectations.
The Data Analytics and Methods task force builds up capability and capacity within EMA and across the European medicines regulatory network to deliver robust evidence for benefit-risk decision-making. This is achieved through expert scientific advice on products under development, strengthened support to marketing authorisation assessments and expert methods advice and data analysis for products on the market.
The Regulatory Science and Innovation task force enables the continuous ‘future-proofing’ of the Agency and the European medicines regulatory network, by addressing key scientific and technological trends and their translation through the development of EMA’s regulatory science strategy, planning and governance. It seeks to offer an enhanced first point of contact service to developers, in particular small and medium-sized enterprises (SMEs) and academia.
The Clinical Studies and Manufacturing task force develops and guides EMA's strategy at European Union and global level to support the facilitation of clinical studies and manufacturing.
The task forces remain flexible to adapt as required by the Agency.